Notably, the increased receipt of endocrine therapy in expansion states may reflect better adoption of the 2016 National Comprehensive Cancer Network guidelines update (recommending neoadjuvant endocrine therapy for early invasive estrogen receptor–rich breast cancer) in these states because of insurance coverage gains following the expansion (8). This evidence concerns the gene ESR1 and breast carcinoma.